Researchers recently sought to evaluate the efficacy and safety of infliximab biosimilar CT-P13 in the treatment of Takayasu arteritis (TAK), a granulomatous inflammatory vasculitis that affects the aorta and can cause aneurysms to form. Some patients with TAK benefit from corticosteroids or second-line, small-molecule immunosuppressive agents, but there is a demand for more effective therapeutic options.
Researchers recently sought to evaluate the efficacy and safety of infliximab biosimilar CT-P13 in the treatment of Takayasu arteritis (TAK), a granulomatous inflammatory vasculitis that affects the aorta and can cause aneurysms to form. Some patients with TAK benefit from corticosteroids or second-line, small-molecule immunosuppressive agents, but there is a demand for more effective therapeutic options.
Investigators designed a single-center, prospective, open-label study that enrolled 12 patients with TAK who received the infliximab biosimilar. One patient was excluded for analysis due to a protocol violation. All participants were female with a mean age of 46.8 years. The trial enrolled patients who had taken a daily dose of 10 mg of prednisolone (or its equivalent), and the dose was maintained for at least 2 weeks prior to the initiation of treatment with CT-P13 and throughout the study.
Patients received intravenous infusions of biosimilar infliximab at a starting dose of 5 mg/kg at weeks 0, 2, and 6, and then every 8 weeks up to week 46. Patients whose erythrocyte sedimentation rate (ESR) had not improved by 50% or more at week 14 were required to increase the dose of CT-P13 by 1.5 mg/kg. Patients were followed to week 54.
The primary endpoint was the achievement of either partial or complete remission by week 30, and secondary endpoints included changes in modified Indian Takayasu Clinical Activity Score (ITAS-A) and serum levels of acute phase reactants at week 30 from baseline.
At week 30, 3 (27.3%) of the 11 patients treated with CT-P13 achieved complete remission, while 6 (54.5%) patients achieved partial remission. Researchers noted that the therapy failed in 2 patients.
Both sustained clinical and serologic response was seen in 4 (44.4%) of the patients who initially achieved either complete or partial remission. The other 3 patients (33.3%) included in the study maintained clinical response but had abnormalities of acute phase reactants, wrote the study authors.
The researchers found that, during the treatment period, no adverse events (AEs) or serious AEs occurred that would call for a discontinuation of treatment. In general, minor infection events were the most frequently reported adverse event, including upper respiratory tract infection and viral keratitis.
Though the trial had a relatively small number of patients, and no definitive conclusions could be drawn regarding the efficacy of infliximab for the treatment of TAK, the researchers said that the findings set a basis for future studies. “This prospective open-label trial of…CT-P13 suggests that CT-P13 therapy may lead to remission or improvement with lower glucocorticoid requirement in TAK. Randomized controlled studies are warranted to assess the long-term efficacy and safety of infliximab and propose precise treatment guidelines for infliximab in TAK,” wrote the investigators.
Reference
Hye Park E, Young Lee E, Jong Lee Y, et al. Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study. Rheumatol Int. 2018; 38(12): 2233-2242. ncbi.nlm.nih.gov/pmc/articles/PMC6223861/. Accessed January 17, 2018.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.